-Global Drug Development Executive with Leadership in Ophthalmology-
LEXINGTON, Mass.--(BUSINESS WIRE)--Jul. 21, 2015--
Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage
biopharmaceutical company focused on the discovery, development, and
commercialization of therapies for ocular diseases, today announced that
Richard N. Spivey, PharmD, PhD, has been appointed to its Board of
Directors.
“I am pleased to welcome Dr. Spivey to Inotek’s Board of Directors,”
said David P. Southwell, President and Chief Executive Officer. “Rich
brings a distinguished background in drug development and regulatory
affairs spanning 30 years at leading pharmaceutical companies, including
most recently at Allergan as Senior Vice President of Global Regulatory
Affairs. We will benefit from Rich’s expert guidance, especially on
regulatory and commercial strategy.”
Dr. Spivey served as Senior Vice President of Global Regulatory Affairs
at Allergan (NYSE: AGN) during the approval and launch of Ozurdex, for
the treatment of diabetic macular edema and Botox, a novel treatment for
spasticity, chronic migraine, neurogenic bladder, overactive bladder and
crow’s feet lines. In addition, he provided ongoing oversight for
development programs in glaucoma and retinal disease, including
drug/device combination products. Before joining Allergan, Dr. Spivey
headed the Research and Development function as Chief Scientific Officer
of Meda AB following their acquisition of MedPointe Pharmaceuticals,
where he was Chief Scientific Officer. Prior to MedPointe, Dr. Spivey
held positions at Pharmacia Corporation (now Pfizer, Inc.),
Schering-Plough Corporation (now Merck & Co.), and
Parke-Davis/Warner-Lambert (now Pfizer, Inc.)
“I believe that trabodenoson, as a novel adenosine mimetic, has the
potential to become an important new therapy for ophthalmologists in
their efforts to stop vision loss in patients with glaucoma,” said Dr.
Spivey. “I am enthusiastic to join Inotek’s Board and help support the
team as we advance the development of trabodenoson monotherapy towards
an NDA.”
About Inotek Pharmaceuticals
Inotek Pharmaceuticals is a clinical-stage biopharmaceutical company
focused on the discovery, development and commercialization of therapies
for glaucoma and other eye diseases. Our lead product candidate,
trabodenoson, is a first-in-class selective adenosine mimetic developed
in Inotek’s laboratories designed to restore the eye’s natural pressure
control mechanism. The development of trabodenoson monotherapy delivered
in a once-daily eye drop formulation will be followed by a fixed-dose
combination of trabodenoson with latanoprost. Additionally, we are
evaluating the potential for selective adenosine mimetics to address
optic neuropathies and other degenerative retinal diseases.
Forward-Looking Statements
This press release contains forward-looking statements, which are
subject to substantial risks, uncertainties and assumptions. You should
not place reliance on these statements. These statements often include
words such as "believe," "expect," "anticipate," "intend," "plan,"
"estimate," "seek," "will," "may" or similar expressions. Accordingly,
you should not place undue reliance on these forward-looking statements.
All such statements speak only as of the date made, and the Company
undertakes no obligation to update or revise publicly any
forward-looking statements, whether as a result of new information,
future events or otherwise.
View source version on businesswire.com: http://www.businesswire.com/news/home/20150721005488/en/
Source: Inotek Pharmaceuticals Corporation
Inotek Contact:
Claudine Prowse, Ph.D., 781-552-4305
Vice
President, Strategy and Investor Relations Officer
cprowse@inotekpharma.com
or
Media
Contact:
MacDougall Biomedical
Karen Sharma, 781-235-3060
ksharma@macbiocom.com
